Expressed prostatic secretion (EPS) volume, total recovered RNA, and RNA expression biomarkers do not improve the prediction of Gleason upgrading over indications from standard clinical parameters in prostate cancer, according to study assessing these methods.

Investigators looked at the performance of the biomarkers in pre-surgical specimens of EPS.

The biomarkers (TMPRSS2: ERG, PCA3, PSA) did not predict upgrading in patients eligible for active surveillance under NCCN guidelines, even though they have been successful in both biopsy outcome prediction, and in the prediction of upstaging in active surveillance eligible patients.

The authors noted that additional biomarkers will be needed in this area.